{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:05:53Z","timestamp":1769299553882,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"L\u00f6rcher Stiftung f\u00fcr Medizinische Forschung"},{"DOI":"10.13039\/501100004869","name":"Westf\u00e4lische Wilhelms-Universit\u00e4t M\u00fcnster","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004869","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Treatment of meningiomas refractory to surgery and irradiation is challenging and effective chemotherapies are still lacking. Recently, in vitro analyses revealed decitabine (DCT, 5-aza-2\u2019\u2013deoxycytidine) to be effective in high-grade meningiomas and, moreover, to induce hypomethylation of distinct oncogenes only sparsely described in meningiomas in vivo yet.<\/jats:p><jats:p>Expression of the corresponding onco- and tumor suppressor genes <jats:italic>TRIM58<\/jats:italic>, <jats:italic>FAM84B<\/jats:italic>, <jats:italic>ELOVL2<\/jats:italic>, <jats:italic>MAL2<\/jats:italic>, <jats:italic>LMO3<\/jats:italic>, and <jats:italic>DIO3<\/jats:italic> were analyzed and scored by immunohistochemical staining and RT-PCR in samples of 111 meningioma patients. Correlations with clinical and histological variables and prognosis were analyzed in uni- and multivariate analyses.<\/jats:p><jats:p>All analyzed oncogenes were highly expressed in meningiomas. Expression scores of <jats:italic>TRIM58<\/jats:italic> tended to be higher in benign than in high-grade tumors 20 vs 16 (<jats:italic>p<\/jats:italic>\u2009=\u2009.002) and all 9 samples lacking <jats:italic>TRIM58<\/jats:italic> expression displayed WHO grade II\/III histology. In contrast, median expression scores for both <jats:italic>FAM84B<\/jats:italic> (6 vs 4, <jats:italic>p<\/jats:italic>\u2009\u2264\u2009.001) and <jats:italic>ELOVL2<\/jats:italic> (9 vs 6, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001) were increased in high-grade as compared to benign meningiomas. <jats:italic>DIO3<\/jats:italic> expression was distinctly higher in all analyzed samples as compared to the reference decitabine-resistant Ben-Men 1 cell line. Increased <jats:italic>ELOVL2<\/jats:italic> expression (score\u2009\u2265\u20098) correlated with tumor relapse in both uni- (HR: 2.42, 95%CI 1.18\u20134.94; <jats:italic>p<\/jats:italic>\u2009=\u2009.015) and multivariate (HR: 2.09, 95%CI 1.01\u20134.44; <jats:italic>p<\/jats:italic>\u2009=\u2009.046) analyses.<\/jats:p><jats:p>All oncogenes involved in DCT efficacy in vitro are also widely expressed in vivo, and expression is partially associated with histology and prognosis. These results strongly encourage further analyses of DCT efficiency in meningiomas in vitro and in situ.<\/jats:p>","DOI":"10.1007\/s10143-022-01789-1","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T13:18:10Z","timestamp":1650547090000},"page":"2767-2775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Expression of decitabine-targeted oncogenes in meningiomas in vivo"],"prefix":"10.1007","volume":"45","author":[{"given":"Julian","family":"Canisius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Christina","family":"Bunk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee C\u00e4cilia","family":"Spille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"St\u00f6gbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Grauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Stummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Senner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3462-3479","authenticated-orcid":false,"given":"Benjamin","family":"Brokinkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"1789_CR1","doi-asserted-by":"publisher","unstructured":"Aoyama M, Ozaki T, Inuzuka H, Tomotsune D, Hirato J, Okamoto Y, Tokita H, Ohira M, Nakagawara A (2005) LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. Cancer Res 65:4587\u20134597. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-4630","DOI":"10.1158\/0008-5472.CAN-04-4630"},{"key":"1789_CR2","doi-asserted-by":"publisher","unstructured":"Bhandari A, Shen Y, Sindan N, Xia E, Gautam B, Lv S, Zhang X (2018) MAL2 promotes proliferation, migration, and invasion through regulating epithelial-mesenchymal transition in breast cancer cell lines. Biochem Biophys Res Commun 504:434\u2013439. https:\/\/doi.org\/10.1016\/j.bbrc.2018.08.187","DOI":"10.1016\/j.bbrc.2018.08.187"},{"key":"1789_CR3","doi-asserted-by":"publisher","unstructured":"Boulagnon-Rombi C, Fleury C, Fichel C, Lefour S, Marchal Bressenot A, Gauchotte G (2017) Immunohistochemical approach to the differential diagnosis of meningiomas and their mimics. J Neuropathol Exp Neurol 76:289\u2013298. https:\/\/doi.org\/10.1093\/jnen\/nlx008","DOI":"10.1093\/jnen\/nlx008"},{"key":"1789_CR4","doi-asserted-by":"publisher","unstructured":"Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, Fanayan S, Emmanuel C, Hacker NF, Sutherland RL, Defazio A, O\u2019Brien PM (2010) MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer 10:497. https:\/\/doi.org\/10.1186\/1471-2407-10-497","DOI":"10.1186\/1471-2407-10-497"},{"key":"1789_CR5","doi-asserted-by":"publisher","unstructured":"Chen D, Chao DL, Rocha L, Kolar M, Nguyen Huu VA, Krawczyk M, Dasyani M, Wang T, Jafari M, Jabari M, Ross KD, Saghatelian A, Hamilton BA, Zhang K, Skowronska-Krawczyk D (2020) The lipid elongation enzyme ELOVL2 is a molecular regulator of aging in the retina. Aging Cell 19:e13100. https:\/\/doi.org\/10.1111\/acel.13100","DOI":"10.1111\/acel.13100"},{"key":"1789_CR6","doi-asserted-by":"publisher","unstructured":"Cheng C, Cui H, Zhang L, Jia Z, Song B, Wang F, Li Y, Liu J, Kong P, Shi R, Bi Y, Yang B, Wang J, Zhao Z, Zhang Y, Hu X, Yang J, He C, Zhao Z, Wang J, Xi Y, Xu E, Li G, Guo S, Chen Y, Yang X, Chen X, Liang J, Guo J, Cheng X, Wang C, Zhan Q, Cui Y (2016) Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma. Gigascience 5:1. https:\/\/doi.org\/10.1186\/s13742-015-0107-0","DOI":"10.1186\/s13742-015-0107-0"},{"key":"1789_CR7","doi-asserted-by":"publisher","unstructured":"Cheng Y, Hou T, Ping J, Chen T, Yin B (2018) LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling. J Exp Clin Cancer Res 37:228. https:\/\/doi.org\/10.1186\/s13046-018-0903-3","DOI":"10.1186\/s13046-018-0903-3"},{"key":"1789_CR8","doi-asserted-by":"publisher","unstructured":"Ding Y, Yang J, Ma Y, Yao T, Chen X, Ge S, Wang L, Fan X (2019) MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2. J Exp Clin Cancer Res 38:498. https:\/\/doi.org\/10.1186\/s13046-019-1492-5","DOI":"10.1186\/s13046-019-1492-5"},{"key":"1789_CR9","doi-asserted-by":"publisher","unstructured":"Freire-Aradas A, Pospiech E, Aliferi A, Giron-Santamaria L, Mosquera-Miguel A, Pisarek A, Ambroa-Conde A, Phillips C, Casares de Cal MA, Gomez-Tato A, Spolnicka M, Wozniak A, Alvarez-Dios J, Ballard D, Court DS, Branicki W, Carracedo A, Lareu MV (2020) A comparison of forensic age prediction models using data from four DNA methylation technologies. Front Genet 11:932. https:\/\/doi.org\/10.3389\/fgene.2020.00932","DOI":"10.3389\/fgene.2020.00932"},{"key":"1789_CR10","doi-asserted-by":"publisher","unstructured":"Gao F, Shi L, Russin J, Zeng L, Chang X, He S, Chen TC, Giannotta SL, Weisenberger DJ, Zada G, Mack WJ, Wang K (2013) DNA methylation in the malignant transformation of meningiomas. PLoS One 8:e54114. https:\/\/doi.org\/10.1371\/journal.pone.0054114","DOI":"10.1371\/journal.pone.0054114"},{"key":"1789_CR11","doi-asserted-by":"publisher","unstructured":"Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, von Deimling A, Stavrinou P, Lefranc F, Lund-Johansen M, Moyal EC, Brandsma D, Henriksson R, Soffietti R, Weller M (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17:e383\u2013391. https:\/\/doi.org\/10.1016\/S1470-2045(16)30321-7","DOI":"10.1016\/S1470-2045(16)30321-7"},{"key":"1789_CR12","doi-asserted-by":"publisher","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, Preusser M, Minniti G, Lund-Johansen M, Lefranc F, Houdart E, Sallabanda K, Le Rhun E, Nieuwenhuizen D, Tabatabai G, Soffietti R, Weller M (2021) EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 23:1821\u20131834. https:\/\/doi.org\/10.1093\/neuonc\/noab150","DOI":"10.1093\/neuonc\/noab150"},{"key":"1789_CR13","doi-asserted-by":"publisher","unstructured":"Gururajan M, Josson S, Chu GC, Lu CL, Lu YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, Posadas EM, Chung LW (2014) miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer. Clin Cancer Res 20:6559\u20136569. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1784","DOI":"10.1158\/1078-0432.CCR-14-1784"},{"key":"1789_CR14","doi-asserted-by":"publisher","unstructured":"Hagemann S, Heil O, Lyko F, Brueckner B (2011) Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One 6:e17388. https:\/\/doi.org\/10.1371\/journal.pone.0017388","DOI":"10.1371\/journal.pone.0017388"},{"key":"1789_CR15","doi-asserted-by":"publisher","unstructured":"Hamm CA, Xie H, Costa FF, Vanin EF, Seftor EA, Sredni ST, Bischof J, Wang D, Bonaldo MF, Hendrix MJ, Soares MB (2009) Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2\u2019-deoxycytidine results in increased tumorigenicity. PLoS One 4:e8340. https:\/\/doi.org\/10.1371\/journal.pone.0008340","DOI":"10.1371\/journal.pone.0008340"},{"key":"1789_CR16","doi-asserted-by":"publisher","unstructured":"He PF, Zhou JD, Yao DM, Ma JC, Wen XM, Zhang ZH, Lian XY, Xu ZJ, Qian J, Lin J (2017) Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Oncotarget 8:41498\u201341507. https:\/\/doi.org\/10.18632\/oncotarget.17241","DOI":"10.18632\/oncotarget.17241"},{"key":"1789_CR17","first-page":"2568","volume":"11","author":"D Jeong","year":"2021","unstructured":"Jeong D, Ham J, Kim HW, Kim H, Ji HW, Yun SH, Park JE, Lee KS, Jo H, Han JH, Jung SY, Lee S, Lee ES, Kang HS, Kim SJ (2021) ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer. Am J Cancer Res 11:2568\u20132589","journal-title":"Am J Cancer Res"},{"key":"1789_CR18","doi-asserted-by":"publisher","unstructured":"Kajiura K, Masuda K, Naruto T, Kohmoto T, Watabnabe M, Tsuboi M, Takizawa H, Kondo K, Tangoku A, Imoto I (2017) Frequent silencing of the candidate tumor suppressor TRIM58 by promoter methylation in early-stage lung adenocarcinoma. Oncotarget 8:2890\u20132905. https:\/\/doi.org\/10.18632\/oncotarget.13761","DOI":"10.18632\/oncotarget.13761"},{"key":"1789_CR19","doi-asserted-by":"publisher","unstructured":"Lall RR, Lall RR, Smith TR, Lee KH, Mao Q, Kalapurakal JA, Marymont MH, Chandler JP (2014) Delayed malignant transformation of petroclival meningioma to chondrosarcoma after stereotactic radiosurgery. J Clin Neurosci 21:1225\u20131228. https:\/\/doi.org\/10.1016\/j.jocn.2013.11.015","DOI":"10.1016\/j.jocn.2013.11.015"},{"key":"1789_CR20","doi-asserted-by":"publisher","unstructured":"Larsen S, Yokochi T, Isogai E, Nakamura Y, Ozaki T, Nakagawara A (2010) LMO3 interacts with p53 and inhibits its transcriptional activity. Biochem Biophys Res Commun 392:252\u2013257. https:\/\/doi.org\/10.1016\/j.bbrc.2009.12.010","DOI":"10.1016\/j.bbrc.2009.12.010"},{"key":"1789_CR21","doi-asserted-by":"publisher","unstructured":"Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S (2010) Genomic landscape of meningiomas. Brain Pathol 20:751\u2013762. https:\/\/doi.org\/10.1111\/j.1750-3639.2009.00356.x","DOI":"10.1111\/j.1750-3639.2009.00356.x"},{"key":"1789_CR22","doi-asserted-by":"publisher","unstructured":"Li J, Li Y, Liu H, Liu Y, Cui B (2017) The four-transmembrane protein MAL2 and tumor protein D52 (TPD52) are highly expressed in colorectal cancer and correlated with poor prognosis. PLoS One 12:e0178515. https:\/\/doi.org\/10.1371\/journal.pone.0178515","DOI":"10.1371\/journal.pone.0178515"},{"key":"1789_CR23","doi-asserted-by":"publisher","unstructured":"Liu M, Zhang X, Cai J, Li Y, Luo Q, Wu H, Yang Z, Wang L, Chen D (2018) Downregulation of TRIM58 expression is associated with a poor patient outcome and enhances colorectal cancer cell invasion. Oncol Rep 40:1251\u20131260. https:\/\/doi.org\/10.3892\/or.2018.6525","DOI":"10.3892\/or.2018.6525"},{"key":"1789_CR24","doi-asserted-by":"publisher","unstructured":"Liu X, Lei Q, Yu Z, Xu G, Tang H, Wang W, Wang Z, Li G, Wu M (2015) MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells. Oncotarget 6:7930\u20137943. https:\/\/doi.org\/10.18632\/oncotarget.3181","DOI":"10.18632\/oncotarget.3181"},{"key":"1789_CR25","doi-asserted-by":"publisher","unstructured":"Molina-Pinelo S, Salinas A, Moreno-Mata N, Ferrer I, Suarez R, Andres-Leon E, Rodriguez-Paredes M, Gutekunst J, Jantus-Lewintre E, Camps C, Carnero A, Paz-Ares L (2018) Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer. Oncotarget 9:4395\u20134410. https:\/\/doi.org\/10.18632\/oncotarget.10611","DOI":"10.18632\/oncotarget.10611"},{"key":"1789_CR26","doi-asserted-by":"publisher","unstructured":"Moskovich D, Finkelshtein Y, Alfandari A, Rosemarin A, Lifschytz T, Weisz A, Mondal S, Ungati H, Katzav A, Kidron D, Mugesh G, Ellis M, Lerer B, Ashur-Fabian O (2021) Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment. Oncogene 40:6248\u20136257. https:\/\/doi.org\/10.1038\/s41388-021-02020-z","DOI":"10.1038\/s41388-021-02020-z"},{"key":"1789_CR27","unstructured":"Perry A, Louis DN, von Deimling A, Sahm F, Rushing EJ, Mawrin C, Claus EB, Loeffler J, Sadetzki S (2016) Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD et al. (eds) WHO Classification of Tumors of the Central Nervous System. International Agency on Cancer Research, Lyon, pp 232\u2013245"},{"key":"1789_CR28","doi-asserted-by":"publisher","unstructured":"Qiu X, Huang Y, Zhou Y, Zheng F (2016) Aberrant methylation of TRIM58 in hepatocellular carcinoma and its potential clinical implication. Oncol Rep 36:811\u2013818. https:\/\/doi.org\/10.3892\/or.2016.4871","DOI":"10.3892\/or.2016.4871"},{"key":"1789_CR29","doi-asserted-by":"publisher","unstructured":"Qiu YS, Jiang NN, Zhou Y, Yu KY, Gong HY, Liao GJ (2018) LMO3 promotes gastric cancer cell invasion and proliferation through Akt-mTOR and Akt-GSK3beta signaling. Int J Mol Med 41:2755\u20132763. https:\/\/doi.org\/10.3892\/ijmm.2018.3476","DOI":"10.3892\/ijmm.2018.3476"},{"key":"1789_CR30","doi-asserted-by":"publisher","unstructured":"Serna E, Morales JM, Mata M, Gonzalez-Darder J, San Miguel T, Gil-Benso R, Lopez-Gines C, Cerda-Nicolas M, Monleon D (2013) Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma. PLoS One 8:e67291. https:\/\/doi.org\/10.1371\/journal.pone.0067291","DOI":"10.1371\/journal.pone.0067291"},{"key":"1789_CR31","doi-asserted-by":"publisher","unstructured":"Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22\u201339. https:\/\/doi.org\/10.1136\/jnnp.20.1.22","DOI":"10.1136\/jnnp.20.1.22"},{"key":"1789_CR32","doi-asserted-by":"publisher","unstructured":"Spille DC, Hess K, Bormann E, Sauerland C, Brokinkel C, Warneke N, Mawrin C, Paulus W, Stummer W, Brokinkel B (2020) Risk of tumor recurrence in intracranial meningiomas: comparative analyses of the predictive value of the postoperative tumor volume and the Simpson classification. J Neurosurg 134:1764\u20131771. https:\/\/doi.org\/10.3171\/2020.4.JNS20412","DOI":"10.3171\/2020.4.JNS20412"},{"key":"1789_CR33","doi-asserted-by":"publisher","unstructured":"Stogbauer L, Thomas C, Wagner A, Warneke N, Bunk EC, Grauer O, Canisius J, Paulus W, Stummer W, Senner V, Brokinkel B (2020) Efficacy of decitabine in malignant meningioma cells: relation to promoter demethylation of distinct tumor suppressor and oncogenes and independence from TERT. J Neurosurg:1\u201310. https:\/\/doi.org\/10.3171\/2020.7.JNS193097","DOI":"10.3171\/2020.7.JNS193097"},{"key":"1789_CR34","doi-asserted-by":"publisher","unstructured":"Tanaka K, Kandori S, Sakka S, Nitta S, Tanuma K, Shiga M, Nagumo Y, Negoro H, Kojima T, Mathis BJ, Shimazui T, Watanabe M, Sato TA, Miyamoto T, Matsuzaka T, Shimano H, Nishiyama H (2022) ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma. Oncol Rep 47. https:\/\/doi.org\/10.3892\/or.2021.8234","DOI":"10.3892\/or.2021.8234"},{"key":"1789_CR35","doi-asserted-by":"publisher","unstructured":"Wong N, Gu Y, Kapoor A, Lin X, Ojo D, Wei F, Yan J, de Melo J, Major P, Wood G, Aziz T, Cutz JC, Bonert M, Patterson AJ, Tang D (2017) Upregulation of FAM84B during prostate cancer progression. Oncotarget 8:19218\u201319235. https:\/\/doi.org\/10.18632\/oncotarget.15168","DOI":"10.18632\/oncotarget.15168"},{"key":"1789_CR36","doi-asserted-by":"publisher","unstructured":"Zhang B, Xiao J, Cheng X, Liu T (2021) MAL2 interacts with IQGAP1 to promote pancreatic cancer progression by increasing ERK1\/2 phosphorylation. Biochem Biophys Res Commun 554:63\u201370. https:\/\/doi.org\/10.1016\/j.bbrc.2021.02.146","DOI":"10.1016\/j.bbrc.2021.02.146"},{"key":"1789_CR37","doi-asserted-by":"publisher","unstructured":"Zhang X, Xu J, Yan R, Zhang Y, Hu Z, Fu H, You Q, Cai Q, Yang D (2020) FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt\/beta-catenin pathway. Aging (Albany NY) 12:6808\u20136822. https:\/\/doi.org\/10.18632\/aging.103044","DOI":"10.18632\/aging.103044"},{"key":"1789_CR38","doi-asserted-by":"publisher","unstructured":"Zhang Y, Li Q, Yu S, Zhu C, Zhang Z, Cao H, Xu J (2019) Long non-coding RNA FAM84B-AS promotes resistance of gastric cancer to platinum drugs through inhibition of FAM84B expression. Biochem Biophys Res Commun 509:753\u2013762. https:\/\/doi.org\/10.1016\/j.bbrc.2018.12.177","DOI":"10.1016\/j.bbrc.2018.12.177"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-022-01789-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-022-01789-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-022-01789-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T09:05:26Z","timestamp":1659517526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-022-01789-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1789"],"URL":"https:\/\/doi.org\/10.1007\/s10143-022-01789-1","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"21 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Westf\u00e4lische Wilhelms-Universit\u00e4t M\u00fcnster and the \u00c4rztekammer Westfalen-Lippe (M\u00fcnster 2007\u2013420-f-S and M\u00fcnster 2018\u2013061-f-S).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}